On June 27, 2024, Coherus BioSciences, Inc. (the ?Company?) entered into an exclusive license and distribution agreement (the ?License Agreement?) with Apotex, Inc. (?Apotex?), pursuant to which, the Company has granted to Apotex an exclusive license under the Company?s rights to toripalimab to commercialize toripalimab within Canada. As previously disclosed, on February 1, 2021, Coherus BioSciences, Inc. (the ?Company?) announced that it had entered into the exclusive license and commercialization agreement (the ?Collaboration Agreement?) with Shanghai Junshi Biosciences Co. Ltd. (?Junshi Biosciences?) for the co-development and commercialization of toripalimab, Junshi Biosciences?

anti-PD-1 antibody, in the United States and Canada. Pursuant to the Collaboration Agreement, the Company has the right to grant sublicenses to third parties to commercialize toripalimab within Canada. Pursuant to the License Agreement, Apotex agreed to pay to the Company an upfront payment of USD 6.25 million.

In addition, Apotex agreed to pay to the Company the USD equivalent of up to an aggregate of up to CAD 51.5 million in milestone payments in connection with the achievement of certain regulatory and sales milestones with respect to toripalimab in Canada. Finally, Apotex agreed to pay to the Company a low double-digit percentage of any future net sales of toripalimab in Canada that the Company will subsequently pay to Junshi Biosciences pursuant to the Collaboration Agreement. The License Agreement term continues until the tenth year after the first commercial sale of toripalimab in Canada, subject to an extension for a subsequent ten year term at the option of Apotex.

Apotex may terminate the License Agreement for any reason after a specified notice period, the License Agreement will terminate automatically if the rights granted to the Company by the Collaboration Agreement are terminated, if there is material breach that is not cured, if there are certain challenges to licensed patents by Apotex and in the case of certain insolvency events.